表紙
市場調査レポート

Covagen AGの製品パイプライン分析

Covagen AG - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 277779
出版日 ページ情報 英文 23 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Covagen AGの製品パイプライン分析 Covagen AG - Product Pipeline Review - 2014
出版日: 2014年05月30日 ページ情報: 英文 23 Pages
概要

Covagen AGは、フィノマー(Fynomer)を製造、販売するバイオテクノロジー企業です。

当レポートでは、Covagen AGにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Covagen AGの基本情報

Covagen AGの概要

  • 主要情報
  • 企業情報

Covagen AG:R&Dの概要

  • 主な治療範囲

Covagen AG:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Covagen AG:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

Covagen AG:薬剤プロファイル

  • COVA-322
  • COVA-208
  • FynomAb-1 for Oncology
  • FynomAb-2 for Oncology

Covagen AG:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Covagen AG:最近のパイプライン動向

Covagen AG:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC04894CDB

Global Markets Direct's, 'Covagen AG - Product Pipeline Review - 2014', provides an overview of the Covagen AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Covagen AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Covagen AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Covagen AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Covagen AG's pipeline products

Reasons to buy

  • Evaluate Covagen AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Covagen AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Covagen AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Covagen AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Covagen AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Covagen AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Covagen AG Snapshot
    • Covagen AG Overview
    • Key Information
    • Key Facts
  • Covagen AG - Research and Development Overview
    • Key Therapeutic Areas
  • Covagen AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Covagen AG - Pipeline Products Glance
    • Covagen AG - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Covagen AG - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Covagen AG - Drug Profiles
    • COVA-322
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COVA-208
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FynomAb-1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FynomAb-2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Covagen AG - Pipeline Analysis
    • Covagen AG - Pipeline Products by Target
    • Covagen AG - Pipeline Products by Molecule Type
    • Covagen AG - Pipeline Products by Mechanism of Action
  • Covagen AG - Recent Pipeline Updates
  • Covagen AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Covagen AG, Key Information
  • Covagen AG, Key Facts
  • Covagen AG - Pipeline by Indication, 2014
  • Covagen AG - Pipeline by Stage of Development, 2014
  • Covagen AG - Monotherapy Products in Pipeline, 2014
  • Covagen AG - Out-Licensed Products in Pipeline, 2014
  • Covagen AG - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Covagen AG - Phase I, 2014
  • Covagen AG - Discovery, 2014
  • Covagen AG - Pipeline by Target, 2014
  • Covagen AG - Pipeline by Molecule Type, 2014
  • Covagen AG - Pipeline Products by Mechanism of Action, 2014
  • Covagen AG - Recent Pipeline Updates, 2014

List of Figures

  • Covagen AG - Pipeline by Top 10 Indication, 2014
  • Covagen AG - Pipeline by Stage of Development, 2014
  • Covagen AG - Monotherapy Products in Pipeline, 2014
  • Covagen AG - Out-Licensed Products in Pipeline, 2014
  • Covagen AG - Pipeline by Top 10 Target, 2014
  • Covagen AG - Pipeline by Top 10 Molecule Type, 2014
  • Covagen AG - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top